ロード中...

Delay and inequalities in the treatment of idiopathic pulmonary fibrosis: the case of two Nordic countries

BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is characterized by progressive loss of lung function with high mortality within the first 5 years from diagnosis. In 2011–2014, two drugs, pirfenidone and nintedanib, have been approved worldwide for prevention of IPF progression. National IPF-registr...

詳細記述

保存先:
書誌詳細
出版年:Multidiscip Respir Med
主要な著者: Pesonen, Ida, Carlson, Lisa, Murgia, Nicola, Kaarteenaho, Riitta, Sköld, Carl Magnus, Myllärniemi, Marjukka, Ferrara, Giovanni
フォーマット: Artigo
言語:Inglês
出版事項: BioMed Central 2018
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5950183/
https://ncbi.nlm.nih.gov/pubmed/29785264
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40248-018-0126-7
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!